U.S. Stem Cell Announces Positive Results for Traumatic Brain Injury (TBI) Patients

Sunrise, FL – December 3, 2015 – U.S. STEM CELL, Inc. (OTC: USRM), a Florida corporation, a leader in the regenerative medicine/cellular therapy industry, developer of novel autologous cell therapies, and provider of physician based stem cell therapies to human and animal patients, is pleased to announce that it has successfully completed five physician based treatments of traumatic brain injury (TBI) patients. The five patients, who received stromal vascular fraction from adipose tissue delivered intrathecally, have been treated over the past 12 months at the US Stem Cell Clinic located in Sunrise, FL

Patient TBI-001, our first patient, has just completed the 12 month follow up and has far exceeded both ours and the patient’s own expectations. Patient TBI-001 presented unable to talk and had difficulty walking. Post treatment, Patient TBI-001 is now able to talk in sentences and walk with full coordination. Additionally, patient TBI-001’s cognitive function has improved, and the patient reports a significant improvement in quality of life. In Patient TBI-001’s own words, “I spent a few months in the hospital and was told by my doctors at one to two years out is where my recovery would stop. At that time I wasn’t able to express myself through talking. I was only able to answer with a yes or no. After treatment, I started noticing improvements and people around me were noticing I was talking and actually engaging in conversation. My walking and coordination also improved.”

For Patients TBI-002 through TBI-005, early progress is being tracked and a more detailed report will be made in the coming months. Of note, however, two of these patients have gone from being in a wheel chair to walking with assistance. One patient is reporting recovery of short term memory.

“We are extremely encouraged by the positive patient results we are seeing from our physician based treatments of TBI patients,” stated Kristin Comella, Chief Scientific Officer. “Today, there are limited treatment options for TBI patients. Our hope is that stem cell therapy will provide relief and an improved quality of life for TBI patients.”

About U.S.Stem Cell, Inc.

US Stemcell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.
Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forwardlooking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q.

Download PDF